MOTS-c Human Evidence: What Studies and the FDA Review Actually Show

Written by the NuLab Editorial Team · Published July 31, 2026 · Last reviewed July 31, 2026

Most human MOTS-c research measures what the body produces naturally; it does not test manufactured MOTS-c.

Quick answer: MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA and studied as a metabolic-stress signal. Human research has measured endogenous MOTS-c in blood and skeletal muscle, including during aging, exercise, and metabolic disease. Those studies show that the peptide is biologically relevant in humans, but they do not establish what administered, manufactured MOTS-c does. FDA's July 2026 briefing review found no published clinical studies evaluating administered MOTS-c in humans for the nominated uses. A Phase 2a study of investigational MOTS-c is now registered and recruiting, but it has no posted results. A completed study of CB4211 involved a related analog—not native-sequence MOTS-c—and likewise has no results posted in the trial registry.

Status as of July 31, 2026: MOTS-c is not an FDA-approved drug. The FDA advisory committee recommended MOTS-c-related bulk substances for possible inclusion on the 503A Bulks List by a reported 7–5 vote, with two abstentions. The recommendation is nonbinding and did not itself authorize compounding or establish safety or effectiveness.

Editorial scope: This article reviews published scientific literature and the FDA regulatory record. It does not evaluate or make claims about any NuLab product. NuLab materials are sold strictly for laboratory research and are not for human or animal consumption.

In this review

• What is a mitochondrial-derived peptide?
• How MOTS-c differs from secretagogue peptides
• Endogenous MOTS-c versus manufactured research material
• What human MOTS-c research actually exists
• What observational studies can—and cannot—show
• What the intervention-trial record shows
• What FDA reviewed in July 2026
• What remains unknown
• Frequently asked questions

What is a mitochondrial-derived peptide?

Mitochondria are best known for their role in cellular energy metabolism, but they also participate in stress signaling and communication with the rest of the cell. They retain a small genome that is separate from the nuclear genome. Researchers have identified short open reading frames within that mitochondrial DNA that can encode biologically active microproteins or peptides, collectively called mitochondrial-derived peptides.

MOTS-c—short for mitochondrial open reading frame of the 12S rRNA type-c—is one of them. It was reported in 2015 as a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA region. Foundational cell and mouse work connected it to metabolic homeostasis and AMPK-associated signaling. Later experiments showed that MOTS-c can move into the nucleus during metabolic stress and influence stress-responsive nuclear gene expression.

That biology makes MOTS-c unusual. The research hypothesis is not simply that mitochondria generate energy, but that mitochondrial genetic information can contribute to a peptide signal that communicates cellular conditions to other compartments.

The distinction is scientifically interesting, but it is not clinical evidence. The original 2015 experiments were principally cell and rodent studies. The 2018 nuclear-translocation work was also mechanistic. These studies help explain why MOTS-c became a serious research subject; they do not establish a human therapeutic outcome.

How MOTS-c differs from secretagogue peptides

MOTS-c is sometimes grouped online with CJC-1295, ipamorelin, and other peptides discussed in performance or metabolic contexts. The grouping can obscure a basic mechanistic difference.

Conventional growth-hormone secretagogue research focuses on compounds that engage receptor systems involved in stimulating growth-hormone release. CJC-1295 is a modified analog of growth hormone-releasing hormone, while ipamorelin has been studied as a growth-hormone secretagogue acting through a different receptor pathway.

MOTS-c is not another version of that signaling strategy. It is a mitochondrial-genome-derived peptide studied in relation to cellular stress, energy sensing, metabolic adaptation, and communication between mitochondrial and nuclear systems. Its proposed actions do not depend on classifying it as a growth-hormone secretagogue.

Research feature	MOTS-c	CJC-1295 or ipamorelin-type secretagogue research
Biological origin or design	Encoded within mitochondrial DNA as a short peptide	Designed or selected to engage hormone-release signaling pathways
Primary research frame	Mitochondrial stress communication, metabolism, and cellular adaptation	Growth-hormone release through GHRH- or ghrelin-receptor-related signaling
Typical mechanistic question	How does a mitochondrial signal alter cellular or systemic responses?	How does receptor activation alter pituitary hormone release?
What the category does not establish	Human benefit from manufactured MOTS-c	Safety, effectiveness, or synergy for an unapproved secretagogue product

This is why a broad phrase such as “metabolic peptide” is not enough to predict mechanism or evidence. Sharing a broad research theme does not demonstrate a shared pathway, comparable evidence, or a useful combination.

Endogenous MOTS-c versus manufactured research material

The word MOTS-c can refer to at least two materially different research subjects.

Endogenous MOTS-c

Endogenous MOTS-c is the peptide detected or inferred within a biological system. Researchers may measure it in plasma, serum, skeletal muscle, or cultured cells. They may then ask whether its concentration differs with age, exercise, genotype, disease state, tissue type, or another variable.

Those measurements concern physiology. The peptide is being observed as part of the system rather than introduced as a manufactured intervention.

Manufactured MOTS-c

Manufactured MOTS-c is a synthesized material intended for laboratory experiments, investigational drug development, or another defined use. Even when the target amino-acid sequence is intended to match the endogenous sequence, the finished material raises separate questions:

• Is the material the free base, acetate, or another chemical form?
• Does its measured mass match the expected molecular identity?
• What sequence-related impurities are present?
• Has the peptide aggregated or degraded?
• What are the water, counterion, residual solvent, microbial, or endotoxin attributes relevant to the experiment?
• Can the analytical result be traced to the exact batch used?

FDA treated MOTS-c free base and MOTS-c acetate as different bulk drug substances in its July 2026 review. The agency also found that inconsistent naming and missing form-specific characterization made it difficult to know which substance a reference standard or commercial name identified.

This difference matters when reading human research. An association between a naturally occurring plasma level and an outcome does not establish the pharmacology, exposure, safety, or effectiveness of manufactured material. It also does not prove that increasing the circulating level from outside the body would reproduce the conditions associated with the endogenous measurement.

For the analytical side of that distinction, see the Journal's guides to HPLC purity and LC-MS identity testing, peptide lot traceability, and lyophilized peptide stability.

What human MOTS-c research actually exists

The human evidence becomes clearer when it is separated by study question.

Evidence type	Representative human research	What it establishes	What it does not establish
Cross-sectional tissue and blood measurement	A 2020 study compared plasma and skeletal-muscle MOTS-c across young, middle-aged, and older men	Endogenous MOTS-c can be measured in human plasma and muscle, and the two compartments may vary differently with age	That administered MOTS-c changes aging, strength, or physical function
Acute exercise response	A 2021 study measured skeletal-muscle and circulating MOTS-c around an exercise session in 10 healthy young men	Endogenous MOTS-c changed after exercise in that small cohort	That manufactured MOTS-c duplicates exercise or improves performance
Exercise-modality comparison	A separate study randomized 30 participants to endurance exercise, resistance exercise, or control	Mitochondrial-derived peptides can be studied dynamically; MOTS-c showed only a trend after endurance exercise in this experiment	A consistent exercise response across populations or a treatment effect
Metabolic-disease association	A 2026 exploratory study compared 22 lean adults with 32 adults with obesity and followed a surgical subgroup	Circulating MOTS-c was higher in the obesity group and was associated with metabolic dysregulation in that dataset	Whether the elevation was causal, compensatory, harmful, protective, or clinically useful
Ongoing native MOTS-c trial	NCT07505745 is a registered Phase 2a randomized trial with an estimated 120 participants	A controlled human administration study is underway	Any result; the registry lists no posted outcomes as of this review
Completed analog trial	NCT03998514 studied CB4211 in 88 healthy adults and adults with fatty liver disease	A related optimized analog entered human drug development	The effects of native MOTS-c; the registry posts no study results

The table shows why the sentence “MOTS-c has human research” can be true yet incomplete. Most published human work concerns endogenous measurement, not administration of manufactured MOTS-c.

What observational studies can—and cannot—show

Human observational work supports the conclusion that MOTS-c is not merely a mouse-research artifact. The peptide or its expression has been measured in human muscle and circulation, and investigators have reported relationships with exercise, age, muscle phenotype, insulin resistance, and other metabolic variables.

But the findings do not reduce to a simple rule such as “more is better.”

In the 2020 healthy-aging study, circulating MOTS-c decreased across age groups while skeletal-muscle expression was higher in the middle-aged and older groups. In the small 2021 exercise experiment, endogenous muscle and circulating levels increased around an acute exercise session. A separate exercise study found only a trend for circulating MOTS-c after endurance exercise and did not find that resting MOTS-c tracked the measured fitness outcomes.

The 2026 obesity study complicates the story further. Its authors reported higher—not lower—circulating MOTS-c in adults with obesity, a nonlinear association with insulin resistance, and no significant change following substantial postoperative weight loss in the followed subgroup. They interpreted the result as potentially compensatory and emphasized the need for validation.

These apparently different findings are not necessarily contradictions. Plasma and tissue measurements may represent different biological compartments. MOTS-c may respond to stress rather than simply mark “health.” Age, sex, exercise state, sampling time, population, assay method, and metabolic condition can all change the observed relationship.

They are also reasons to resist causal language. An observational association cannot show whether MOTS-c caused an outcome, responded to it, or changed alongside another process. Even an exercise experiment that measures an endogenous response tests what the body produced after exercise; it does not test what an external manufactured preparation would do.

What the intervention-trial record shows

An ongoing trial of investigational MOTS-c

ClinicalTrials.gov record NCT07505745 describes a randomized, placebo-controlled Phase 2a study of investigational MOTS-c in adults with prediabetes and overweight or obesity. The record lists an estimated enrollment of 120, an actual start in February 2026, recruiting status, and an estimated primary completion in February 2027. No results were posted when this article was reviewed.

That makes the study important to watch, but not evidence of an outcome. Trial registration describes a hypothesis, design, endpoints, and planned analysis. It does not show whether the intervention is effective or safe.

The FDA briefing document states that the agency did not identify published studies evaluating administration of MOTS-c-related bulk substances to humans. The ongoing registry record does not contradict that conclusion: it has not produced posted or peer-reviewed results.

The completed CB4211 study tested an analog

ClinicalTrials.gov record NCT03998514 describes a completed Phase 1a/1b study of CB4211 in 88 healthy adults and adults with nonalcoholic fatty liver disease. CB4211 was developed as an optimized analog related to MOTS-c; it is not interchangeable with native-sequence MOTS-c.

The registry identifies safety, tolerability, pharmacokinetic, and pharmacodynamic objectives but displays no posted results. Sponsor announcements and conference material have circulated, but they do not replace a complete peer-reviewed report or registry results dataset.

CB4211 therefore belongs in the MOTS-c development history, but not as direct proof about manufactured native MOTS-c. A related analog can differ in sequence, stability, exposure, target engagement, and product quality. Its trial cannot be silently relabeled as a completed MOTS-c trial.

What FDA reviewed in July 2026

The FDA meeting agenda listed obesity and osteoporosis as the uses evaluated for MOTS-c free base and MOTS-c acetate. That wording identifies the regulatory context for the committee's discussion. It does not mean FDA found that either substance treats those conditions.

The agency's MOTS-c briefing document provides the more precise account:

• A nominator originally proposed MOTS-c for insulin resistance, obesity, osteoporosis, vascular calcification, muscle and fat metabolism, and longevity.
• The nomination was later withdrawn, but FDA chose to evaluate MOTS-c free base and acetate on its own initiative.
• FDA said the nomination lacked sufficient information for a full evaluation of the proposed uses and that the agency did not identify clinical studies evaluating those uses.
• Neither form had an applicable USP or NF drug-substance monograph, and neither was a component of an FDA-approved drug.
• FDA considered both substances insufficiently characterized, citing inconsistent naming and missing information about impurities, aggregates, endotoxins, and finished-product attributes.
• The agency found no published human administration evidence with which to evaluate effectiveness and inadequate information to assess human safety and immunogenicity risk.
• FDA staff therefore proposed not adding MOTS-c free base or acetate to the 503A Bulks List.

The advisory committee reached a different recommendation. Contemporaneous reporting placed the vote at 7 in favor, 5 against, and 2 abstentions. That was a recommendation about whether the bulk substances should move forward in the 503A process—not a drug approval or a finding that obesity or osteoporosis benefits were established.

The legal status did not change on the day of the vote. As explained in the Journal's broader review of the six favorable peptide recommendations, FDA must still consider the record and complete further agency action, normally including rulemaking, before a substance is formally added to the list.

What remains unknown

The preclinical record gives researchers multiple hypotheses. The human intervention record has not yet answered them.

The primary molecular targets are not fully resolved

AMPK-associated signaling, folate and purine pathways, nuclear translocation, and stress-responsive gene expression all appear in the mechanistic literature. FDA nevertheless noted that the molecular targets through which MOTS-c acts remain uncertain and that predicting affected organs is difficult.

Endogenous concentration does not define an external intervention

No established conversion links a measured plasma or tissue level to the exposure created by a manufactured material. The body's production, compartmentalization, degradation, and timing may be part of the biology being observed.

Human pharmacology of native MOTS-c remains unsettled

The ongoing Phase 2a study may eventually provide controlled information, but no results are available. Published human pharmacokinetic, pharmacodynamic, exposure-response, interaction, and longer-term data for administered native MOTS-c remain absent or insufficient.

Human safety and immunogenicity are not characterized

FDA highlighted uncertainty about peptide aggregation, peptide-related impurities, anti-drug immune responses, and the lack of clinical safety information. A manufactured sequence cannot be evaluated independently of its form, formulation, impurity profile, and finished-product controls.

Osteoporosis remains particularly indirect

The osteoporosis rationale in the FDA record was based on nonclinical work, including cell and rodent models. No published clinical study identified by FDA evaluated administered MOTS-c for osteoporosis.

Analytical comparability is incomplete

Free base and acetate are distinct bulk drug substances, and a common name may be applied inconsistently. Without form-specific reference standards and validated methods, two materials labeled “MOTS-c” cannot be assumed to be analytically or biologically equivalent.

Frequently asked questions

Is MOTS-c FDA approved?

No. MOTS-c is not an FDA-approved drug. The July 2026 committee recommendation concerned possible inclusion of MOTS-c-related bulk substances on the 503A Bulks List, which is a separate regulatory question.

Did FDA determine that MOTS-c treats obesity or osteoporosis?

No. The meeting agenda listed obesity and osteoporosis as the uses evaluated for the compounding review. FDA's briefing document said the available information was insufficient, identified no published human administration studies for the nominated uses, and proposed against adding the substances to the list.

Has MOTS-c been studied in humans?

Yes, but the type of study matters. Published human research has primarily measured endogenous MOTS-c in blood or tissue. A randomized Phase 2a trial of investigational MOTS-c is recruiting, but it has no posted results. That is different from having completed evidence that administered MOTS-c produces a human outcome.

Is CB4211 the same as MOTS-c?

No. CB4211 is a related optimized analog that entered human clinical development. Its completed study is relevant to the broader development history but cannot establish the effects of native-sequence MOTS-c.

Is MOTS-c a growth-hormone secretagogue?

Not in the conventional sense used for peptides such as ipamorelin or CJC-1295-related compounds. MOTS-c is studied as a mitochondrial-derived stress and metabolic signal rather than primarily as a receptor-mediated stimulator of growth-hormone release.

Does an exercise-related rise in endogenous MOTS-c mean manufactured MOTS-c reproduces exercise?

No. The finding shows that endogenous MOTS-c responded to exercise in a particular study population. It does not demonstrate that administering a manufactured peptide recreates exercise physiology or produces the same outcomes.

What did the 7–5 committee vote change?

It gave MOTS-c free base and acetate a favorable advisory recommendation in the 503A process. It did not add them to the final list, approve a drug, establish a benefit, or immediately change compounding eligibility.

The bottom line

MOTS-c is a legitimate emerging-science subject because it links mitochondrial genetics, cellular stress signaling, metabolism, and human physiology. The human observational literature supports the conclusion that endogenous MOTS-c is measurable and responsive—but it also shows that the biology is more complicated than “higher is better.” Plasma and tissue levels can move differently, exercise findings are not uniform, and metabolic disease associations may reflect compensation rather than causation.

The intervention evidence is much earlier. FDA found no published human studies administering MOTS-c-related bulk substances for the nominated uses. A new Phase 2a trial is recruiting but has no results. The completed CB4211 program tested a related analog, not native MOTS-c, and its registry contains no results.

The July committee vote matters as a policy signal. It does not close the scientific gaps. For now, the strongest reading is that MOTS-c has meaningful preclinical research and informative human physiology studies, while controlled evidence for administered native MOTS-c remains an open question.

Source record

• U.S. Food and Drug Administration. July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee.
• U.S. Food and Drug Administration. Briefing Document for MOTS-c-Related Bulk Drug Substances. July 2026.
• Lee C, Zeng J, Drew BG, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism. 2015;21(3):443–454.
• Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metabolism. 2018;28(3):516–524.e7.
• D'Souza RF, Woodhead JST, Hedges CP, et al. Increased Expression of the Mitochondrial Derived Peptide, MOTS-c, in Skeletal Muscle of Healthy Aging Men Is Associated With Myofiber Composition. Aging. 2020;12(6):5244–5258.
• Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c Is an Exercise-Induced Mitochondrial-Encoded Regulator of Age-Dependent Physical Decline and Muscle Homeostasis. Nature Communications. 2021;12:470.
• Woodhead JST, D'Souza RF, Hedges CP, et al. Acute Endurance Exercise Stimulates Circulating Levels of Mitochondrial-Derived Peptides in Humans. American Journal of Physiology—Endocrinology and Metabolism. 2021;321(3):E370–E375.
• Xing L, Lu B, Zhu X, et al. Systemic MOTS-c Levels Are Increased in Adults With Obesity in Association With Metabolic Dysregulation and Remain Unchanged After Weight Loss. 2026.
• ClinicalTrials.gov. MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity, NCT07505745.
• ClinicalTrials.gov. Phase 1a/1b Study of CB4211, NCT03998514.
• STAT. FDA Advisory Panel Backs Epitalon and MOTS-c, Rejects Emideltide. July 24, 2026.

NuLab products are intended strictly for laboratory research use only and are not for human or animal consumption. This article does not provide medical, dosing, administration, or personal-use guidance.